Press Releases

Date	Title	PDF Version
May 03, 2019	New England Journal of Medicine Publishes Positive Phase 3 PREVENT Data for SOLIRIS® (eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
Apr 26, 2019	Alexion Receives Positive CHMP Opinion for ULTOMIRIS® (ravulizumab) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)
Apr 25, 2019	Alexion Reports First Quarter 2019 Results
Apr 12, 2019	Alexion to Report First Quarter Results on Thursday, April 25, 2019
Apr 04, 2019	Alexion Finalizes Settlement To Resolve Allegations Related To Support Of Patient Assistance Charities
Mar 20, 2019	Alexion and Zealand Pharma Announce Collaboration to Discover and Develop Peptide Therapies for Complement-Mediated Diseases
Mar 20, 2019	Alexion and Affibody Announce Partnership to Co-Develop Anti-FcRn Affibody® Molecule
Mar 05, 2019	Alexion to Present at the Cowen 39th Annual Health Care Conference
Feb 28, 2019	Alexion Employees Raise Hands to Raise Awareness and #RallyforRare on Rare Disease Day
Feb 22, 2019	FDA Grants Priority Review and Accepts sBLA of SOLIRIS® (Eculizumab) as a Treatment for Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Search